Clinical trial
Fludarabine and Cyclophosphamide With or Without Rituximab in Patients With…
NCT00281918 · Hoffmann-La Roche, Industry · Completed
Key facts
| NCT number | NCT00281918 |
|---|---|
| Title | Fludarabine and Cyclophosphamide With or Without Rituximab in Patients With Previously Untreated Chronic B-Cell Lymphocytic Leukemia |
| Official title | Phase III Trial of Combined Immunochemotherapy With Fludarabine, Cyclophosphamide and Rituximab (FCR) Versus Chemotherapy With Fludarabine and Cyclophosphamide (FC) Alone in Patients With Previously Untreated Chronic Lymphocytic Leukaemia |
| Acronym | CLL-8 |
| Lead sponsor | Hoffmann-La Roche, Industry |
| Collaborators | German CLL Study Group |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Leukemia |
| Intervention type | Drug |
| Interventions | Rituximab, Cyclophosphamide, Fludarabine Phosphate |
| Enrollment | 817 |
| Start date | Jul 1, 2003 |
| Primary completion | Jul 1, 2007 |
| Completion | Oct 1, 2011 |
| First posted | Jan 25, 2006 |
| Last update posted | Sep 19, 2013 |
| Countries | Australia, Austria, Belgium, Czechia, Denmark, France, Germany, Israel, Italy, New Zealand, Spain |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: